The development and progression of esophageal adenocarcinoma (EAC) is a multi-step process that involves the progression of Barretts esophagus (BE) to low-grade dysplasia (LGD), highgrade- dysplasia (HGD) and then EAC. This sequence results from the accumulation of genetic and epigenetic alterations in esophageal epithelial cells. The aberrant methylation of 5'gene promoter associated CpG islands, which can silence the expression of tumor suppressor genes, is the major epigenetic alteration in EAC that has been recognized to date, and begins at the pre-cancer phase of EAC formation. Notably, the DNA methylation events are also intimately associated with environmental exposures such as folate, tobacco, etc. (1, 2) The identification of genetic and epigenetic alterations has led to the largely still unrealized hope that these molecular events can be used for the prevention or early detection of BE and/or EAC. We propose that this unrealized potential is primarily a consequence of the lack of sufficiently complex analysis of the molecular alterations in most studies of BE and EAC, which has resulted in the lack of discovery of markers that could be effective biomarkers. In addition, a large well-annotated cohort of BE and EAC patients that has sufficient power to identify prognostic and predictive molecular markers has been difficult to assemble, but is critical to the success of these studies. Recently, reliable highthroughput, genome wide methylation assays have become available, making the genome-wide assessment of methylated genes in BE and EAC feasible. By virtue of the nature of genes affected by epigenetic alterations, it is likely that the comprehensive methylation profiles generated by such new technology will be useful for determining prognosis, for predicting the response to treatment, and for assessing the effect of environmental factors on the molecular pathogenesis of BE and EAC. The project will be conducted in a two-phase process with Phase 1 involving the use of HumanMethylation450 arrays, a comprehensive review of the published literature, and results from methylation array studies previously carried out in our lab. We will examine both novel and known methylated genes to ultimately determine a panel of promising methylated genes that will function as BE or EAC biomarkers and assess if these methylated genes are involved in the molecular pathogenesis of familial vs. sporadic BE as well as in the recurrence of BE after ablation therapy (Aims 1, 2 and 4). In Phase 2 (Aim 3), these results will be used to develop a focused and rational panel of methylated genes that serve as accurate biomarkers for BE. These results will subsequently be translated into esophageal brushing-based diagnostic and/or predictive BE biomarkers (Aim 3). Finally, in Aim 4, we will also determine whether methylated genes can be used to identify individuals at risk for recurrence of BE from neosquamous epithelium after radiofrequency ablation (RFA).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163060-04
Application #
8721886
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
4
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
Venkitachalam, Srividya; Guda, Kishore (2017) Altered glycosyltransferases in colorectal cancer. Expert Rev Gastroenterol Hepatol 11:5-7
Morris, Shelli M; Davison, Jerry; Carter, Kelly T et al. (2017) Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms. Int J Cancer 140:853-863
Cummings, Linda C; Thota, Prashanthi N; Willis, Joseph E et al. (2017) A nonrandomized trial of vitamin D supplementation for Barrett's esophagus. PLoS One 12:e0184928
Luebeck, E Georg; Curtius, Kit; Hazelton, William D et al. (2017) Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma. Clin Epigenetics 9:113
Krishnamoorthi, Rajesh; Borah, Bijan; Heien, Herbert et al. (2016) Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. Gastrointest Endosc 84:40-46.e7
Curtius, Kit; Wong, Chao-Jen; Hazelton, William D et al. (2016) A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus. PLoS Comput Biol 12:e1004919
Kendall, Bradley J; Rubenstein, Joel H; Cook, Michael B et al. (2016) Inverse Association Between Gluteofemoral Obesity and Risk of Barrett's Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol 14:1412-1419.e3
Fecteau, Ryan E; Kong, Jianping; Kresak, Adam et al. (2016) Association Between Germline Mutation in VSIG10L and Familial Barrett Neoplasia. JAMA Oncol 2:1333-1339
Blum, Andrew E; Venkitachalam, Srividya; Guo, Yan et al. (2016) RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Res 76:5628-5633
Venkitachalam, Srividya; Revoredo, Leslie; Varadan, Vinay et al. (2016) Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Sci Rep 6:23642

Showing the most recent 10 out of 57 publications